DocJax

Declassified record · U.S. Department of Energy

Summary Data on FY 93 Human Radiation Research Exposure

Dated
Sep 12, 1994
Document type
Correspondence
Length
1 page
Open the original scanArchive record OSTI ID 16010155 · public domain

Document text

Machine-read from the scan, so expect some errors. Lines that couldn’t be read are left out.

Page 1

DEPARTMENT OF THE ARMY U.S. ARMY MEDICAL DEPARTMENT CENTER AND SCHOOL FORT SAM HOUSTON, TEXAS 70294-0100 MEMORANDUM FOR Captain John F. Jemionek, MSC, USN, Office of the Director of Defense Research & Engineering, Washington, DC 20301-3030 SUBJECT: Summary Data on FY93 Human Radiation Research Exposure 1. This letter responds to a request from the Director of Environmental & Life Sciences for information about human radiation exposure under research conditions. This response pertains to the Clinical Investigation Program of the United States Army's Health Services Command (HSC) for fiscal year (FY) 1 9 9 3 . HSC is responsible for the delivery of health care to Armed Forces health-care beneficiaries at Army hospitals and clinics in the United States and Panama. The authority for and responsibilities of HSC's Clinical Investigation Program is codified in Army Regulation 40-38. 2. Attached are detail summary sheets for 235 clinical-investigation protocols active during at least part of FY93. Many are still ongoing. The sheets are grouped by the facility hosting the research: BAMC - Brooke Army Medical Center DDEAMC - Dwight D. Eisenhower Army Medical Center FAMC - Fitzsimons Army Medical Center MAMC - Madigan Army Medical Center TAMC - Tripler Army Medical Center WAMC - Womack Army Medical Center WBAMC - William Beaumont Army Medical Center WRAMC - Walter Reed Army Medical Center 3. These sheets are derived from the annual progress report completed b: Army hospital conducting clinical investigations. The complete annual progress reports for all Army teaching hospitals for FY93 were submitted earlier this year for the use of Senator Jay Rockefeller. 4. Additional information may be obtained by contacting MAJ John D. Grabenstein, Regulatory Affairs Pharmacist, at DSN 471-2511 or commercial 210Chief, Clinical Investigation Consultant to The Army Surgeon General for Clinical Investigation CF: COL Erdtmann, OTSG